Diplomat Pharmacy (NYSE:DPLO) had its price objective hoisted by research analysts at Needham & Company LLC from $24.00 to $26.00 in a research report issued to clients and investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price points to a potential upside of 9.84% from the stock’s current price.
Several other analysts also recently commented on the company. Leerink Swann upgraded Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Monday, December 11th. Deutsche Bank began coverage on Diplomat Pharmacy in a research note on Monday, December 4th. They issued a “buy” rating and a $22.00 target price for the company. Robert W. Baird downgraded Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $24.00 to $18.00 in a research note on Thursday, November 16th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Mizuho raised their target price on Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, November 7th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Diplomat Pharmacy has an average rating of “Buy” and an average price target of $20.94.
Shares of Diplomat Pharmacy (NYSE DPLO) traded up $0.48 on Monday, hitting $23.67. The stock had a trading volume of 1,083,600 shares, compared to its average volume of 1,106,283. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34. The firm has a market cap of $1,600.00, a P/E ratio of 197.25, a PEG ratio of 3.62 and a beta of 0.62. Diplomat Pharmacy has a 12 month low of $12.29 and a 12 month high of $23.90.
In other news, CFO Atul Kavthekar bought 2,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were purchased at an average price of $15.00 per share, with a total value of $30,000.00. Following the transaction, the chief financial officer now directly owns 2,000 shares in the company, valued at $30,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Joel Saban bought 10,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were purchased at an average cost of $15.24 per share, for a total transaction of $152,400.00. Following the transaction, the president now owns 12,000 shares in the company, valued at $182,880. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 15,000 shares of company stock worth $228,780. 30.20% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its holdings in shares of Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after purchasing an additional 2,794 shares during the period. First Allied Advisory Services Inc. bought a new stake in shares of Diplomat Pharmacy in the 2nd quarter worth approximately $183,000. SG Americas Securities LLC bought a new stake in shares of Diplomat Pharmacy in the 3rd quarter worth approximately $191,000. BNP Paribas Arbitrage SA raised its holdings in shares of Diplomat Pharmacy by 57.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,992 shares of the company’s stock worth $207,000 after purchasing an additional 5,116 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in shares of Diplomat Pharmacy by 478.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 14,600 shares of the company’s stock worth $216,000 after purchasing an additional 12,076 shares during the period. 72.21% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/10/diplomat-pharmacy-dplo-pt-raised-to-26-00.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
What are top analysts saying about Diplomat Pharmacy? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Diplomat Pharmacy and related companies.